ClinicalTrials.gg
Not yet recruitingNCT06115629SARONG-IIUpdated Nov 3, 2023

Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial

A Phase 3 interventional study of Surveillance protocol in Esophageal Cancer and Gastric Cancer, sponsored by University of Dublin, Trinity College. Not yet recruiting at 13 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-03.

Sponsored by University of Dublin, Trinity College · Phase 3, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
952
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 30 studies in Esophageal Neoplasms with a site in Sweden — 8 open to participants now, 8 under way, 1 of them phase 3. Esophageal Neoplasms · Sweden.

Planned enrollment
Largest of 19
952 · median 80
Started
2023
with 1 other
Phase 3
2 of 30
1 open now
Registered
28th of 30
by date

Among the 30 studies in Esophageal Neoplasms with a site in Sweden, this one has the largest planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2023, is one of 2 in phase 3, and was the 28th registered.

Esophageal Neoplasms

1,874 studies on the registry are indexed under Esophageal Neoplasms; 502 are open to participants now.

Browse Esophageal Neoplasms studies →

Open to participants now

8 of the 30 studies in Esophageal Neoplasms with a site in Sweden are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →

Who these studies take

Of the 387 Esophageal Neoplasms studies recruiting now, 245 (63%) set no upper age limit and 75 (19%) stop at 75 or younger; 20 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Esophageal Neoplasms with a site in Sweden, or all of them as a file.
02

Study summary

Cancer of the food pipe (oesophagus) and stomach are increasingly common. Currently, most patients with cancer of the oesophagus and stomach are treated with surgery with or without additional chemotherapy or radiotherapy. In recent years there have been improvements in survival from these two cancers, due to better therapies, less invasive surgery and earlier detection. Despite these improvements, in around half of patients treated with surgery, the cancer will return, usually within the first three years.

At present there is very little evidence as to how patients who have been treated for cancer of the oesophagus or stomach should be followed up after surgery and whether different methods of follow-up could improve survival. Currently, national and international guidelines do not provide consistency in their recommendations for follow-up after surgery.

The SARONG-II study will investigate if regular radiological scans can lead to earlier detection of a cancer returning, at a stage when it may be more readily treatable. This means that participants who agree to take part will be allocated by chance to either more intensive imaging surveillance (including regular radiological scans and a camera test (endoscopy)) or clinical follow-up.

The study aims to recruit at least 952 participants in Europe over a 32-month period. Patients undergoing surgery for oesophageal or stomach cancer will be invited to participate in the study at around 4 to 8 weeks after their surgery.

(i) The imaging surveillance group will receive a review in clinic or by telephone with a member of the surgical team, and a radiological scan at 6, 12, 18, 24, 30 and 36 months after randomisation. They will also receive endoscopy at 12 months after randomisation (ii) The clinical surveillance group will receive a review in clinic or by telephone at 6, 12, 18, 24, 30 and 36 months. After this they will be either discharged to their local doctor or receive a review in clinic with a member of the surgical team every year according to local practice

The main aim of this study will be to determine whether earlier detection of cancer through more intensive follow-up results in improved survival and better quality of life for patients with oesophagus or stomach cancer. The investigators anticipate the results of the study may have significant practice-changing impact for patients undergoing follow-up after surgery for oesophagus and stomach cancer.

Read the detailed description

It is an encouraging trend that the overall survival rate for oesophagogastric cancer has doubled over the last 20 years. For patients with locally advanced disease treated with curative intent, 5 year survival in the modern era approaches 50%. Relevant factors include earlier diagnosis, improvements in staging, and quality improvements in the standard modalities of surgery, chemotherapy and radiation therapy, increasingly delivered in high volume centers. When local or systemic failure occurs, where therapeutic nihilism may have once prevailed, a menu of therapeutic options can now be considered, such as immunotherapy, salvage locoregional surgery, resection of oligometastatic disease, brachytherapy, radiofrequency ablation (RFA) and stereotactic radiation therapy.

In the context of this changing landscape and expanded armamentarium, a key question, as yet unresolved, is how patients treated with curative intent should be optimally followed-up. The options include an intensive imaging surveillance approach using clinical assessment, cross-sectional imaging, and endoscopy, or one purely based on symptomatic follow-up to trigger further investigation.

The debate for oesophagogastric cancer is limited by a paucity of evidence. This may reflect both a lack of attention to this topic in research, with no RCTs, and relatively poor quality cohort and observational studies with considerable heterogeneity. The approach to surveillance varies considerably internationally. In Japan, a nationwide survey reported that that high intensity surveillance was common, with endoscopic surveillance utilized in over 80% of patients, in contrast to approximately 6% in Australia and New Zealand. In Europe, the European Registration of Cancer Care (EURECCA) Upper Gastrointestinal group reported a brief summary from 10 Centers, and highlighted substantial differences in elements of surveillance, in particular of cross-sectional imaging, which was sought in just 40% of patients. Guidelines also vary, for instance the European Society for Medical Oncology guidelines currently state, "With the exception of endoscopic or operative salvage after initial non-operative management, there is no evidence that regular follow-up has an impact on survival outcomes", while the UK NICE guidelines state, "for people without symptoms or evidence of residual disease after treatment for oesophagogastric cancer with curative intent, do not offer routine clinical follow-up or radiological surveillance solely for the detection of recurrent disease".

It is clear that research is urgently required on this important topic that will inform everyday practice and future guidelines. In this context, a European collaborative multicenter study was established with the primary objective of assessing the current situation in specialist centers internationally and its impact on survival and quality of life.

In this study, the investigators first surveyed 27 European centres, and identified marked variation in surveillance practices, with only 37% of centres providing routine radiologic surveillance for detection of recurrence, and only 19% undertaking routine surveillance endoscopy. The investigators then undertook a European multicentre cohort study, which included 4682 patients. At median follow-up 60 months, 47.5% developed recurrence, oligometastatic in 39%. Intensive surveillance, defined as a computed tomography scan undertaken at least annually for three years after surgery, was associated with reduced symptomatic recurrence and increased tumor-directed therapy. On multivariable analysis, no overall survival benefit was observed among all patients (HR1.01 [0.89-1.13]), but overall survival was improved following intensive surveillance for those who underwent surgery alone and those with lower pathological (y)pT stages. Intensive surveillance was associated with similar overall HRQL. This study established that there is widespread heterogeneity in surveillance protocols in Europe, and the vast majority of centres agreed there is a need for an RCT examining this issue.

The SARONG-II study is an international multicentre, open-label, two-arm, parallel design, superiority randomised controlled trial. 952 patients (476 in each of two trial arms) will be recruited from approximately 14 sites in Europe. Participants will be randomised to either imaging surveillance every 6 months for 36 months and an endoscopy at 12 months postrandomisation or clinical follow-up for 36 months.

Primary Outcome Measure:

All-cause mortality defined as death from any cause. Participants who have not been observed to die during the course of the study will have their survival time censored at their last known follow-up date.

Secondary Outcome Measures:

  1. a) Disease-specific mortality, defined as known oesophageal or gastric cancer recurrence at the time of death.

    b) Pattern of tumour recurrence, defined as the incidence of loco-regional or distant recurrence.

    c) Treatment of tumour recurrence, ie. the requirement for chemotherapy, surgery, immunotherapy, radiotherapy, chemoradiotherapy, best supportive care or other as determined by the clinical team at the treating site.

    d) Rates of oligometastatic (one site) tumour recurrence. e) Rates of multi-metastatic (several sites) tumour recurrence.

  2. HRQoL, including anxiety or depression and worry of cancer returning as measured by the following validated questionnaires: EQ- 5D-5L, EORTC QLQ-C30 and QLQ-OG25 and Cancer Worry Scale (CWS).
  3. Incremental cost per quality adjusted life year (QALY)
03

Conditions studied

  • Esophageal Cancer
  • Gastric Cancer

Keywords

  • Surveillance
  • Cancer recurrence
  • Quality of life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

A patient will be eligible for inclusion in this study if all of the following criteria apply:

  1. Has undergone surgical resection for curatively intended treatment of oesophageal or gastric cancer (adenocarcinoma and squamous cell carcinoma) with or without /adjuvant chemotherapy or radiotherapy or immunotherapy (or in combination).
  2. Aged 18 years or over
  3. Willing and able to give

A patient with not be eligible for the trial if any of the following apply:

  1. Other cancer(s) undergoing treatment or surveillance
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
952 participants (estimated)

Study arms

  • Experimental
    Imaging surveillance

    Computed tomography scan every 6 months for 3 years postoperatively. Upper gastrointestinal endoscopy at 12 months postoperatively.

    Other: Surveillance protocol

  • No intervention
    Clinical surveillance

    Clinical review every 6 months for 3 years postoperatively with further investigation according to symptoms.

Interventions

  • OtherSurveillance protocol

    Imaging surveillance will entail a computed tomography scan of the chest, abdomen and pelvis, as well as clinical review, every 6 months for 36 months post surgery along with an endoscopy at 12 months post surgery.

06

What researchers measure

Primary outcomes

  1. All-cause mortality

    All-cause mortality defined as death from any cause. Participants who have not been observed to die during the course of the study will have their survival time censored at their last known follow-up date.

    Time frame: 36 months post randomisation

Secondary outcomes

  1. Disease-specific mortality

    Disease-specific mortality, defined as known oesophageal or gastric cancer recurrence at the time of death.

    Time frame: 36 months post randomisation

  2. Pattern of recurrence

    Pattern of tumour recurrence, defined as the incidence of loco-regional or distant recurrence.

    Time frame: 36 months post randomisation

  3. Treatment of recurrence

    Treatment of tumour recurrence, ie. the requirement for chemotherapy, surgery, immunotherapy, radiotherapy, chemoradiotherapy, best supportive care or other as determined by the clinical team at the treating site.

    Time frame: 36 months post randomisation

  4. Oligometastatic recurrence as determined using the OligoMetastatic Esophagogastric Cancer (OMEC) classification system

    Rates of oligometastatic tumour recurrence

    Time frame: 36 months post randomisation

  5. Multimetastatic recurrence

    Rates of multi-metastatic (several sites) tumour recurrence

    Time frame: 36 months post randomisation

  6. Overall quality of life as determined by the global health status using the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire C30

    Using European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire C30, reported as a linear transformed outcome ranging from 0-100.

    Time frame: 36 months post randomisation

  7. Cost effectiveness as determined by incremental cost per quality adjusted life year

    Incremental cost per quality adjusted life year (QALY) determined using the 5-level EQ-5D version (EQ-5D-5L) as well as healthcare utilisation costs measured in Euro.

    Time frame: 36 months post randomisation

  8. Fear of cancer recurrence as determined by the cancer worry scale score

    Measured from 1-4

    Time frame: 36 months post randomisation

07

Study locations

13 sites
08

References and documents

Publications

  • Elliott JA, Klevebro F, Mantziari S, Markar SR, Goense L, Johar A, Lagergren P, Zaninotto G, van Hillegersberg R, van Berge Henegouwen MI, Schafer M, Nilsson M, Hanna GB, Reynolds JV; ENSURE Study Group. Neoadjuvant Chemoradiotherapy Versus Chemotherapy for the Treatment of Locally Advanced Esophageal Adenocarcinoma in the European Multicenter ENSURE Study. Ann Surg. 2023 Nov 1;278(5):692-700. doi: 10.1097/SLA.0000000000006018. Epub 2023 Jul 20. PubMed 37470379 ↗
  • Gujjuri RR, Clarke JM, Elliott JA, Rahman SA, Reynolds JV, Hanna GB, Markar SR; ENSURE Group Study. Predicting long-term survival and time-to-recurrence after esophagectomy in patients with esophageal cancer - Development and validation of a multivariate prediction model. Ann Surg. 2023 Jun;277(6):971-978. doi: 10.1097/SLA.0000000000005538. Epub 2022 Jul 15. No abstract available. PubMed 37193219 ↗
  • Elliott JA, Markar SR, Klevebro F, Johar A, Goense L, Lagergren P, Zaninotto G, van Hillegersberg R, van Berge Henegouwen MI, Nilsson M, Hanna GB, Reynolds JV; ENSURE Study Group. An International Multicenter Study Exploring Whether Surveillance After Esophageal Cancer Surgery Impacts Oncological and Quality of Life Outcomes (ENSURE). Ann Surg. 2023 May 1;277(5):e1035-e1044. doi: 10.1097/SLA.0000000000005378. Epub 2022 Jan 27. PubMed 35129466 ↗
  • Chidambaram S, Sounderajah V, Maynard N, Underwood T, Markar SR. Evaluation of postoperative surveillance strategies for esophago-gastric cancers in the UK and Ireland. Dis Esophagus. 2022 Feb 11;35(2):doab057. doi: 10.1093/dote/doab057. PubMed 34426840 ↗
  • Chidambaram S, Sounderajah V, Maynard N, Markar SR. Evaluation of post-operative surveillance strategies for esophageal and gastric cancers: a systematic review and meta-analysis. Dis Esophagus. 2022 Dec 14;35(12):doac034. doi: 10.1093/dote/doac034. PubMed 35788834 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2023; primary completion for Nov 2026, 36 months later.

Of 57 phase 3 interventional studies under Esophageal Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 113. This study's planned 36 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2023
First posted
Nov 3, 2023
StartEst.
Nov 2023
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2029
Last update
Nov 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06115629
Lead sponsor
University of Dublin, Trinity College
Collaborators
Trinity St. James's Cancer Institute, University of Oxford, Karolinska Institutet
Responsible party
Dr Jessie A Elliott (Clinical Lecturer, University of Dublin, Trinity College) — Principal investigator
First posted
Nov 3, 2023
Start date
Nov 2023 (estimated)
Primary completion
Nov 2026 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 3, 2023

Study contacts

Jessie A Elliott, PhD FRCS
Contact
SARONG@tcd.ie
+353 1 410 3900
Jessie A Elliott, PhD FRCS
principal investigator · Trinity St. James's Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion